Aim: We aimed to evaluate the effect of echocardiographically demonstrated right ventricular dysfunction (RVD) on time in therapeutic range (TTR) in heart failure (HF) patients receiving warfarin therapy. Methods: A total of 893 consecutive HF patients were included and classified into 4 different subgroups: HF with preserved ejection fraction (HFpEF) without RVD (n = 373), HF with reduced EF (HFrEF) without RVD (n = 215), HFpEF with RVD (n = 106) and HFrEF with RVD (n = 199). Groups were compared according to baseline, demographic and clinical data and the characteristics of warfarin therapy. Results: Presence of RVD yielded lower median TTR values both in HFpEF and HFrEF patients. RVD, current smoking, New York Heart Association functional class III/IV, hypertension, diabetes mellitus, pulmonary disease, prior transient ischemic attack or stroke, chronic kidney disease (CKD) stage 4/5 and CKD stage 3 were found to be independent predictors of poor anticoagulation control in multivariate logistic regression analysis. Conclusions: The present study demonstrated that presence of RVD in HF increases the risk for poor anticoagulation.

Keywords:
Warfarin, Heart failure, Right ventricular dysfunction, Time in therapeutic range
1.
Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G; American College of Chest Physicians: Pharmacology and management of the vitamin K antagonists: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133(6 suppl):160S-198S.
2.
Du Breuil AL, Umland EM: Outpatient management of anticoagulation therapy. Am Fam Physician 2007;75:1031-1042.
3.
Phillips KW, Ansell J: Outpatient management of oral vitamin K antagonist therapy: defining and measuring high-quality management. Expert Rev Cardiovasc Ther 2008;6:57-70.
4.
Schulman S, Crowther MA: How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood 2012;119:3016-3023.
5.
Demirkan K, Stephens MA, Newman KP, Self TH: Response to warfarin and other oral anticoagulants: effects of disease states. South Med J 2000;93:448-454; quiz 455.
6.
Self TH, Reaves AB, Oliphant CS, Sands C: Does heart failure exacerbation increase response to warfarin? A critical review of the literature. Curr Med Res Opin 2006;22:2089-2094.
7.
Reisner EH Jr, Norman J, Field WW, Brown R: The effect of liver dysfunction on the response to dicumarol. Am J Med Sci 1949;217:445-447.
8.
Stats D, Davison S: The increased hypoprothrombinemic effect of a small dose of dicumarol in congestive heart failure. Am J Med Sci 1949;218:318-323.
9.
Peyman MA: The significance of haemorrhage during the treatment of patients with the coumarin anticoagulants. Acta Med Scand Suppl 1958;339:1-62.
10.
Petitti DB, Strom BL, Melmon KL: Prothrombin time ratio and other factors associated with bleeding in patients treated with warfarin. J Clin Epidemiol 1989;42:759-764.
11.
Penning-van Beest FJ, van Meegen E, Rosendaal FR, Stricker BH: Characteristics of anticoagulant therapy and comorbidity related to overanticoagulation. Thromb Haemost 2001;86:569-574.
12.
Visser LE, Bleumink GS, Trienekens PH, Vulto AG, Hofman A, Stricker BH: The risk of overanticoagulation in patients with heart failure on coumarin anticoagulants. Br J Haematol 2004;127:85-89.
13.
Hylek EM, Regan S, Go AS, Hughes RA, Singer DE, Skates SJ: Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med 2001;135:393-400.
14.
Oates A, Jackson PR, Austin CA, Channer KS: A new regimen for starting warfarin therapy in out-patients. Br J Clin Pharmacol 1998;46:157-161.
15.
Pokorney SD, Simon DN, Thomas L, Fonarow GC, Kowey PR, Chang P, Singer DE, Ansell J, Blanco RG, Gersh B, Mahaffey KW, Hylek EM, Go AS, Piccini JP, Peterson ED; Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators: Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: results from ORBIT-AF registry. Am Heart J 2015;170:141-148.e1.
16.
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; Authors/Task Force Members: 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129-2200.
17.
Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E: A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993;69:236-239.
18.
Kaatz S: Determinants and measures of quality in oral anticoagulation therapy. J Thromb Thrombolysis 2008;25:61-66.
19.
Simon MA: Assessment and treatment of right ventricular failure. Nat Rev Cardiol 2013;10:204-218.
20.
Haeusler KG, Laufs U, Endres M: Chronic heart failure and ischemic stroke. Stroke 2011;42:2977-2982.
21.
Brigden ML, Kay C, Le A, Graydon C, McLeod B: Audit of the frequency and clinical response to excessive oral anticoagulation in an out-patient population. Am J Hematol 1998;59:22-27.
22.
Ripley TL, Harrison D, Germany RE, Adamson PB: Effect of heart failure exacerbations on anticoagulation: a prospective, observational, pilot cohort study. Clin Ther 2010;32:506-514.
23.
Lee VW, You JH, Lee KK, Chau TS, Waye MM, Cheng G: Factors affecting the maintenance stable warfarin dosage in Hong Kong Chinese patients. J Thromb Thrombolysis 2005;20:33-38.
24.
Rose AJ, Ozonoff A, Henault LE, Hylek EM: Warfarin for atrial fibrillation in community-based practise. J Thromb Haemost 2008;6:1647-1654.
25.
Apostolakis S, Sullivan RM, Olshansky B, Lip GY: Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score. Chest 2013;144:1555-1563.
26.
Valentova M, von Haehling S, Krause C, Ebner N, Steinbeck L, Cramer L, Doehner W, Murin J, Anker SD, Sandek A: Cardiac cachexia is associated with right ventricular failure and liver dysfunction. Int J Cardiol 2013;169:219-224.
27.
Valentova M, von Haehling S, Bauditz J, Doehner W, Ebner N, Bekfani T, Elsner S, Sliziuk V, Scherbakov N, Murín J, Anker SD, Sandek A: Intestinal congestion and right ventricular dysfunction: a link with appetite loss, inflammation, and cachexia in chronic heart failure. Eur Heart J 2016;37:1684-1691.
28.
Rose AJ, Reisman JI, Razouki Z, Ozonoff A: Percent time in range with warfarin as a performance measure: how long a sampling frame is needed? Jt Comm J Qual Patient Saf 2015;41:561-568.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.